Patent · US Active

Antibodies directed against prothrombin fragment F1+2, the preparation and use thereof

US8063180B2 · kind B2 · utility

2Cited by

3References

20Claims

0Family size

Assignee

Seimens Healthcare Diagnostics Products GmbH · DE

Inventors

Stefan Teigelkamp · Niederwalgern, DE
Konrad Braun · Allendorf (Lumda), DE

Key dates

Filing date	Nov 16, 2009
Grant date	Nov 22, 2011
Priority date	—
Expiry date	Nov 16, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y304/21005
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention relates to antibodies directed against F1+2, to the preparation and use thereof, especially in therapy and diagnosis. The antibodies bind to an epitope on the N-terminal half of the F2 fragment of prothrombin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.